Sanofi (SNY)
$48.28
+0.3
(+0.63%)▲
Sanofi SA is a French multinational pharmaceutical company that focuses on the research, development, and distribution of healthcare products and services.
Performance
- $48.03$48.54$48.28
0.52%
Downside
Day's Volatility :1.05%
Upside
0.54%
- $45.22$58.97$48.28
6.34%
Downside
52 Weeks Volatility :23.32%
Upside
18.13%
Returns
| Period | Sanofi | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -14.2% | -7.3% | 0.0% |
6 Months | 0.71% | -0.2% | 0.0% |
1 Year | 1.32% | 9.9% | 0.0% |
3 Years | -0.04% | 8.8% | -24.1% |
Highlights
Market Capitalization | 120.7B |
Book Value | $58.10 |
Dividend Share | 0.0 |
Dividend Yield | 4.25% |
Earnings Per Share (EPS) | 1.9 |
PE Ratio | 25.25 |
PEG Ratio | 0.75 |
Wall Street Target Price | 63.491 |
Profit Margin | 9.3% |
Operating Margin TTM | 28.81% |
Return On Assets TTM | 4.16% |
Return On Equity TTM | 5.82% |
Revenue TTM | 48.4B |
Revenue Per Share TTM | 19.36 |
Quarterly Revenue Growth YOY | 11.5% |
Gross Profit TTM | 31.7B |
EBITDA | 12.5B |
Diluted Eps TTM | 1.9 |
Quarterly Earnings Growth YOY | 0.12 |
EPS Estimate Current Year | 4.36 |
EPS Estimate Next Year | 4.9 |
EPS Estimate Current Quarter | 1.39 |
EPS Estimate Next Quarter | 0.97 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 31.51%
Technicals Summary
Sell
Neutral
Buy
Sanofi is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Sanofi | -11.15% | 0.71% | 1.32% | -0.04% | 2.94% |
 Eli Lilly And Company | -16.21% | -7.41% | 26.45% | 187.29% | 536.77% |
 Johnson & Johnson | -3.55% | 7.47% | 2.57% | -2.53% | 13.11% |
 Merck & Co. Inc. | -4.62% | -21.34% | -2.22% | 25.29% | 15.73% |
 Novo Nordisk A/s | -7.34% | -21.64% | 1.15% | 94.25% | 273.55% |
 Abbvie Inc | -5.8% | 13.91% | 27.22% | 51.88% | 101.63% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Sanofi | 25.25 | 25.25 | 0.75 | 4.36 | 0.06 | 0.04 | 0.04 | 58.1 |
Eli Lilly And Company | 80.9 | 80.9 | 0.71 | 13.16 | 0.65 | 0.14 | 0.01 | 15.83 |
Johnson & Johnson | 25.45 | 25.45 | 0.92 | 9.96 | 0.21 | 0.08 | 0.03 | 29.14 |
Merck & Co. Inc. | 20.89 | 20.89 | 0.07 | 7.74 | 0.28 | 0.11 | 0.03 | 17.58 |
Novo Nordisk A/s | 34.03 | 34.03 | 1.54 | 22.7 | 0.89 | 0.21 | 0.01 | 27.07 |
Abbvie Inc | 59.84 | 59.84 | 0.41 | 10.94 | 0.56 | 0.08 | 0.04 | 3.41 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Sanofi | Buy | $120.7B | 2.94% | 25.25 | 9.3% |
Eli Lilly And Company | Buy | $711.9B | 536.77% | 80.9 | 20.48% |
Johnson & Johnson | Buy | $370.8B | 13.11% | 25.45 | 16.74% |
Merck & Co. Inc. | Buy | $252.6B | 15.73% | 20.89 | 19.23% |
Novo Nordisk A/s | Buy | $472.8B | 273.55% | 34.03 | 35.01% |
Abbvie Inc | Buy | $303.5B | 101.63% | 59.84 | 9.22% |
Insights on Sanofi
Increasing Revenue
Revenue is up for the last 3 quarters, 11.11B → 14.15B (in $), with an average increase of 11.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 1.11B → 2.81B (in $), with an average increase of 60.5% per quarter
Vs ABBV
In the last 1 year, Abbvie Inc has given 27.6% return, outperforming this stock by 25.3%
Vs LLY
In the last 3 years, Eli Lilly And Company has given 49.1% return, outperforming this stock by 50.8%
Institutional Holdings
Dodge & Cox
3.04%Morgan Stanley - Brokerage Accounts
1.18%Fisher Asset Management, LLC
0.53%Bank of America Corp
0.45%Amvescap Plc.
0.42%BlackRock Inc
0.40%
Corporate Announcements
Sanofi Dividends September,2024
In the quarter ending September,2024. Sanofi has declared dividend of $2.04
Read More
Company Information
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo
Organization | Sanofi |
Employees | 86088 |
CEO | Mr. Paul Hudson |
Industry | Health Technology |
